Author:
Grujic Mirjana,Alim Md Abdul,Hellman Lars,Peterson Magnus,Pejler Gunnar
Abstract
AbstractMast cells (MCs) are known to have a pathological impact in a variety of settings, in particular in allergic conditions. There is also limited evidence implicating MCs in diabetes, raising the possibility that MC function may be influenced by alterations in glucose levels. However, it is not known whether MCs are directly affected by elevated glucose concentrations. Moreover, it is not known which glucose transporters that are expressed by MCs, and whether MCs are dependent on glucose transporters for activation. Here we addressed these issues. We show that MCs express high levels of both glucose transporter 1 (GLUT1/Slc2A1) and GLUT3 (Slc2A3). Further, we show that the inhibition of either GLUT1 or GLUT3 dampens both MC degranulation and cytokine induction in response to IgE receptor crosslinking, and that combined GLUT1 and GLUT3 inhibition causes an even more pronounced inhibition of these parameters. In contrast, the inhibition of GLUT1 or GLUT3, or combined GLUT1 and GLUT3 inhibition, had less impact on the ability of the MCs to respond to activation via compound 48/80. Elevated glucose concentrations did not affect MC viability, and had no stimulatory effect on MC responses to either IgE receptor crosslinking or compound 48/80. Altogether, these findings reveal that MCs are strongly dependent on glucose transport via GLUT1 and/or GLUT3 for optimal responses towards IgE-mediated activation, whereas MC functionality is minimally affected by elevated glucose levels. Based on these findings, antagonists of GLUT1 and GLUT3 may be considered for therapeutic intervention in allergic conditions.
Funder
Vetenskapsrådet
Knut och Alice Wallenbergs Stiftelse
Cancerfonden
Hjärt-Lungfonden
Familjen Erling-Perssons Stiftelse
Uppsala University
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Metcalfe, D.D., D. Baram, and Y.A. Mekori. 1997. Mast cells. Physiological Reviews 77: 1033–1079.
2. Masini, M., M. Suleiman, M. Novelli, L. Marselli, P. Marchetti, and V. De Tata. 2021. Mast cells and the pancreas in human type 1 and type 2 diabetes. Cells 10: 1875.
3. Mlac, M., M. Melato, and G. Marin. 1975. Mast cells in the islets of Langerhans. A study of their behaviour in connection with diabetes and with insular amyloidosis. Virchows Archiv A, Pathological Anatomy and Histopathology 365: 213–220.
4. Dong, J., L. Chen, Y. Zhang, N. Jayaswal, I. Mezghani, W. Zhang, et al. 2020. Mast cells in diabetes and diabetic wound healing. Advances in Therapy 37: 4519–4537.
5. Gurish, M.F., and K.F. Austen. 2012. Developmental origin and functional specialization of mast cell subsets. Immunity 37: 25–33.